Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R7HL
|
|||
| Drug Name |
LXS196
|
|||
| Synonyms |
XXJXHXJWQSCNPX-UHFFFAOYSA-N; 1874276-76-2; LXS-196; NVP-LXS196; SCHEMBL17506262; CHEMBL3982723; LXS 196; BDBM251460; EX-A2690; BCP20781; ZINC584641445; CS-7529; HY-101569; US9452998, 9; 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [2] | ||
| Company |
Novartis Oncology East Hanover, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23F3N8O
|
|||
| Canonical SMILES |
CC1(CCN(CC1)C2=C(N=CC=C2)NC(=O)C3=NC(=CN=C3N)C4=C(C=CC=N4)C(F)(F)F)N
|
|||
| InChI |
1S/C22H23F3N8O/c1-21(27)6-10-33(11-7-21)15-5-3-9-29-19(15)32-20(34)17-18(26)30-12-14(31-17)16-13(22(23,24)25)4-2-8-28-16/h2-5,8-9,12H,6-7,10-11,27H2,1H3,(H2,26,30)(H,29,32,34)
|
|||
| InChIKey |
XXJXHXJWQSCNPX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1874276-76-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein kinase C (PRKC) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03947385) Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.